No connection

Search Results

AIDX vs IINN

AIDX
20/20 Biolabs, Inc.
BEARISH
Price
$1.91
Market Cap
$19.9M
Sector
Healthcare
AI Confidence
60%
IINN
Inspira Technologies Oxy B.H.N. Ltd.
BEARISH
Price
$0.42
Market Cap
$18.5M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AIDX
--
IINN
--
Forward P/E
AIDX
--
IINN
-0.61
P/B Ratio
AIDX
159.17
IINN
6.54
P/S Ratio
AIDX
9.75
IINN
64.07
EV/EBITDA
AIDX
-6.62
IINN
-1.18

Profitability

Gross Margin
AIDX
29.56%
IINN
0.69%
Operating Margin
AIDX
-169.59%
IINN
-4713.84%
Profit Margin
AIDX
-182.82%
IINN
0.0%
ROE
AIDX
-503.12%
IINN
-397.89%
ROA
AIDX
-53.92%
IINN
-126.98%

Growth

Revenue Growth
AIDX
0.4%
IINN
--
Earnings Growth
AIDX
--
IINN
--

Financial Health

Debt/Equity
AIDX
--
IINN
0.21
Current Ratio
AIDX
0.6
IINN
1.56
Quick Ratio
AIDX
0.5
IINN
1.12

Dividends

Dividend Yield
AIDX
--
IINN
--
Payout Ratio
AIDX
0.0%
IINN
0.0%

AI Verdict

AIDX BEARISH

AIDX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.

Strengths
Company has established market presence
Risks
Low profit margin of -182.8%
Weak financial trend (Piotroski F-Score: 3/9)
Weak ROE of -503.1%
IINN BEARISH

IINN exhibits severe fundamental distress, characterized by a Piotroski F-Score of 4/9, which barely maintains a 'stable' rating despite catastrophic operational metrics. The company's operating margin of -4713.84% and a Price-to-Sales ratio of 64.07 indicate a massive disconnect between market valuation and actual revenue generation. With a 5-year price decline of 91% and a technical trend score of 0/100, the stock is in a persistent freefall. The absence of an Altman Z-Score and Graham Number further underscores the lack of positive earnings or stable equity to support a traditional valuation.

Strengths
Low Debt/Equity ratio (0.21)
Current Ratio of 1.56 suggests adequate short-term liquidity
Quick Ratio of 1.12 indicates ability to cover immediate liabilities
Risks
Extreme operational inefficiency (Operating Margin: -4713.84%)
Negligible Gross Margin (0.69%) suggesting no pricing power or high COGS
Severe valuation bubble relative to sales (P/S: 64.07)

Compare Another Pair

AIDX vs IINN: Head-to-Head Comparison

This page compares 20/20 Biolabs, Inc. (AIDX) and Inspira Technologies Oxy B.H.N. Ltd. (IINN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile